# Idorsia Pharmaceuticals Ltd. clinical trials: 103 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 103 trials with Idorsia Pharmaceuticals Ltd. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Idorsia Pharmaceuticals Ltd.: 103 rows for $5.15, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/idorsia-pharmaceuticals-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 103
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 103, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 28, 2026 | NCT07843329 | A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During... | Idorsia Pharmaceuticals Ltd. | Phase 3 | Recruiting | Insomia Disorder | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843329) |
| August 21, 2026 | NCT07778667 | A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease | Idorsia Pharmaceuticals Ltd. | Phase 3 | Recruiting | Fabry Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778667) |
| August 13, 2026 | NCT07762638 | Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302 | Idorsia Pharmaceuticals Ltd. | Not applicable | Available | Fabry Disease | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762638) |
| June 25, 2026 | NCT07667569 | A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo | Idorsia Pharmaceuticals Ltd. | Phase 2 | Recruiting | Non-Segmental Vitiligo | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667569) |
| January 29, 2025 | NCT06799884 | A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Drug Drug Interaction | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06799884) |
| July 12, 2024 | NCT06498128 | Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ® | Idorsia Pharmaceuticals Ltd. | Observational | Terminated | Insomnia | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06498128) |
| May 1, 2024 | NCT06393504 | Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant) | Idorsia Pharmaceuticals Ltd. | Observational | Active not recruiting | Insomnia Disorder | 2,095 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06393504) |
| May 26, 2023 | NCT05877222 | A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and... | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05877222) |
| January 27, 2023 | NCT05702177 | A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words... | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05702177) |
| November 30, 2022 | NCT05632393 | A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05632393) |
| October 27, 2022 | NCT05597020 | A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia | Idorsia Pharmaceuticals Ltd. | Phase 4 | Completed | Insomnia Disorder, Nocturia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05597020) |
| September 22, 2022 | NCT05549531 | A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single... | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05549531) |
| July 29, 2022 | NCT05480488 | A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy... | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05480488) |
| July 29, 2022 | NCT05480475 | A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in... | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05480475) |
| July 14, 2022 | NCT05458193 | A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Obstructive Sleep Apnea of Adult | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05458193) |
| June 21, 2022 | NCT05423717 | Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to \< 18 Years With Insomnia... | Idorsia Pharmaceuticals Ltd. | Phase 2 | Completed | Insomnia | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05423717) |
| February 24, 2022 | NCT05254548 | A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole... | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05254548) |
| January 19, 2022 | NCT05196399 | Bioequivalence Study of Different Aprocitentan Tablet Formulations | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy Subjects | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05196399) |
| November 17, 2021 | NCT05123820 | Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470 | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Drug Drug Interaction, Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05123820) |
| May 24, 2021 | NCT04899219 | A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04899219) |
| March 15, 2021 | NCT04798209 | A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04798209) |
| February 15, 2021 | NCT04753164 | Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating... | Idorsia Pharmaceuticals Ltd. | Phase 2 | Completed | Binge-Eating Disorder | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04753164) |
| October 29, 2020 | NCT04608513 | A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of... | Idorsia Pharmaceuticals Ltd. | Phase 1 | Completed | Healthy | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04608513) |
| July 14, 2020 | NCT04470713 | Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2 | Idorsia Pharmaceuticals Ltd. | Observational | Completed | GM1 Gangliosidosis, GM2 Gangliosidosis, Gaucher Disease, Type 2, Tay-Sachs Disease, AB Variant Gangliosidosis GM2... | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04470713) |
| June 30, 2020 | NCT04452006 | A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the... | Idorsia Pharmaceuticals Ltd. | Phase 1 | Terminated | Healthy | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04452006) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 66 |
| Phase 2 | 16 |
| Phase 3 | 16 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 90 |
| Terminated | 7 |
| Recruiting | 3 |
| Available | 1 |
| Active not recruiting | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Sleep Initiation and Maintenance Disorders | 11 |
| Subarachnoid Hemorrhage | 5 |
| Fabry Disease | 5 |
| Vasospasm, Intracranial | 3 |
| Renal Insufficiency | 3 |
| Essential Hypertension | 2 |
| Rhinitis, Allergic, Seasonal | 2 |
| Hemorrhage | 2 |
| Pulmonary Arterial Hypertension | 2 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Binge-Eating Disorder | 1 |
| Rhinitis, Allergic | 1 |
| Hypersensitivity | 1 |
| Malaria | 1 |
| Gangliosidosis, GM1 | 1 |
| Gangliosidoses, GM2 | 1 |
| Gaucher Disease | 1 |
| Tay-Sachs Disease | 1 |
| Tay-Sachs Disease, AB Variant | 1 |
| Sandhoff Disease | 1 |
| Nocturia | 1 |
| Epilepsy, Reflex | 1 |
| Liver Diseases | 1 |
| Sleep Apnea, Obstructive | 1 |
| Asthma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Life insurance agencies in the United States](https://specstream.ai/data/businesses/life-insurance-agencies/united-states)
- [Clinical laboratories in the United States](https://specstream.ai/data/businesses/clinical-laboratories/united-states)
- [Stone suppliers in the United States](https://specstream.ai/data/businesses/stone-suppliers/united-states)
- [Iron fabricators in the United States](https://specstream.ai/data/businesses/iron-fabricators/united-states)
- [Cajun and Creole restaurants in the United States](https://specstream.ai/data/businesses/cajun-and-creole-restaurants/united-states)
